APOLIPOPROTEIN-E IS A KINETIC BUT NOT A THERMODYNAMIC INHIBITOR OF AMYLOID FORMATION - IMPLICATIONS FOR THE PATHOGENESIS AND TREATMENT OF ALZHEIMER-DISEASE

Citation
Kc. Evans et al., APOLIPOPROTEIN-E IS A KINETIC BUT NOT A THERMODYNAMIC INHIBITOR OF AMYLOID FORMATION - IMPLICATIONS FOR THE PATHOGENESIS AND TREATMENT OF ALZHEIMER-DISEASE, Proceedings of the National Academy of Sciences of the United Statesof America, 92(3), 1995, pp. 763-767
Citations number
31
Categorie Soggetti
Multidisciplinary Sciences
ISSN journal
00278424
Volume
92
Issue
3
Year of publication
1995
Pages
763 - 767
Database
ISI
SICI code
0027-8424(1995)92:3<763:AIAKBN>2.0.ZU;2-B
Abstract
The apolipoprotein E4 (APOE4) allele is associated with an early age o f onset of the nonfamilial form of Alzheimer disease (AD) and with inc reased beta protein amyloid deposition in the brain. These two observa tions may both arise from an effect of the apoE family of proteins on the rate of in vivo amyloidogenesis. We report here that apoE3, the co mmon apoE isoform, is an in vitro amyloid nucleation inhibitor at phys iological concentrations. A significant delay in the onset of amyloid fibril formation by the beta-amyloid protein of AD (beta 1-40) was obs erved at a low apoE3 concentration (40 nM), corresponding to an apoE3/ beta protein molar ratio of 1:1000. The inhibitory activity of a prote olytic fragment of apoE3, containing the N-terminal 191 amino acids, i s comparable to the native protein, whereas the C-terminal fragment ha s no activity. ApoE4 is equipotent or slightly less potent than apoE3, which may be due to its inability to form a disulfide dimer, since th e apoE3 dimer is a significantly more potent nucleation inhibitor than apoE4. Neither apoE3 nor apoE4 inhibits the seeded growth of amyloid or affects the solubility or structure of the amyloid fibrils, indicat ing that apoE is not a thermodynamic amyloid inhibitor. We propose tha t the linkage between the APOE4 allele and AD reflects the reduced abi lity of APOE4 homozygotes to suppress in vivo amyloid formation.